SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavaxs quarterly report, higher full-year revenue outlook and Sanofi vaccine-trial milestone are driving discussion, with bullish traders pointing to improved finances and licensing potential. Shares are falling despite the upbeat results, as skeptics question whether milestone income can become recurring revenue and call for more partnerships and clearer pipeline progress.

Corsair Gaming, Inc. designs and supplies hardware components for personal computers. It operates through the Gamer and Creator Peripherals, and Gaming Components and Systems segments. The Gamer and Creator Peripherals segment offers gaming keyboards, mice, headsets, controllers, and gaming gear including capture cards, Stream Decks, USB microphones, studio accessories, and EpocCam software, as well as coaching and training services. The Gaming Components and Systems segment focuses on creating power supply units, or PSUs, cooling solutions, computer cases, DRAM modules, prebuilt, and custom-built gaming PCs. The company was founded by Andrew J. Paul in 1994 and is headquartered in Milpitas, CA.

Corsair Gaming Inc

Strong quarterly results, improving margins and raised full-year guidance have fueled a sharp rally, with bullish traders pointing to Corsairs turnaround and potential short squeeze. Others caution that the move could fade, while debate continues over whether the improved performance can persist.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVDA is caught in a broad semiconductor selloff as traders worry that political pressure and possible data-center restrictions could slow AI infrastructure spending and chip demand. The community is divided: some fear a lasting capex slowdown, while others argue projects will move to friendlier regions and that the market reaction overstates the risk.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan D. Green on March 5, 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is under pressure after a Q3 earnings miss, with a legal, tax and regulatory reserve reducing reported revenue and weighing on GAAP results. Traders are split: bears focus on the headline miss, while bulls point to growth in bookings and riders, stronger adjusted EBITDA, and in-line Q4 guidance.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

RKTs rebound has drawn attention, with traders citing strong quarterly results and market-share gains despite a difficult mortgage market, alongside heavy call-option activity. Bullish traders see room for recovery, while skeptics point to elevated rates, weak housing demand and cautious outlook concerns.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

P&Gs better-than-expected quarterly results have driven a sharp rally, with traders also pointing to demand for defensive consumer-staples stocks. Bulls see resilient demand and safe-haven appeal, while skeptics question the premium valuation and warn that higher costs are squeezing margins.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is drawing attention after a steep selloff that traders variously attribute to broad biotech and market weakness, thin trading, and concerns about the CEOs share sale, cash needs, and transparency around the planned prostate-cancer BLA filing. The community is split between buying the dip on confidence in the clinical data and upcoming pipeline updates, and warning that financing and execution uncertainty could keep pressure on the shares.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo is under pressure amid a broader AI-infrastructure selloff and concern that MaxLinear plans to compete for share in the active electrical cable market Credo dominates. Bears see rising competition and customer concentration as risks, while bulls argue demand is expanding and the selloff overstates the threat.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALABs sharp selloff is being discussed as part of a broader pullback in AI hardware, with traders questioning whether data-center spending and financing can sustain demand for its connectivity products and whether its valuation leaves room for further downside. Bulls call the move sentiment-driven and see the AI infrastructure thesis intact, while bears point to customer concentration and possible buildout slowdowns.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflares quarterly earnings beat and raised outlook sparked a sharp after-hours rebound following a steep selloff. Traders are split on whether accelerating growth can outweigh the stocks rich valuation and margin concerns, especially amid broad market weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Tiziana Life Sciences Stock Gaining Thursday?

Tiziana Life Sciences (TLSA) stock jumps 21% following an MOU to test intranasal foralumab combo therapy for MS.read more...

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

Tiziana Life Sciences reports reduced brain inflammation in its third Phase 2 trial patient treated with intranasal foralumab for MSA.read more...

Tiziana Life Sciences Stock Rises Over 9% After Multiple Sclerosis Trial Enrollment Update

Equity

The biotechnology company has completed enrollment in its placebo-controlled study of intranasal foralumab, with late-stage data expected in 2026.

Wall Street Zen Downgrades Tiziana Life Sciences (NASDAQ:TLSA) to Sell

Wall Street Zen lowered Tiziana Life Sciences from a "hold" rating to a "sell" rating in a research note on Saturday...

Tiziana Life Sciences (NASDAQ:TLSA) Trading 6.8% Higher - Here's What Happened

Tiziana Life Sciences (NASDAQ:TLSA) Trading 6.8% Higher - Here's What Happened...

Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum

Tiziana Life Sciences shares jump on intranasal foralumab data, while technical indicators point to mixed momentum.read more...

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 4.4% - Should You Sell?

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4% - Should You Sell...

Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 0.7% - Here's What Happened

Tiziana Life Sciences (NASDAQ:TLSA) Shares Up 0.7% - Should You Buy...

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 3.1% - Should You Buy?

Tiziana Life Sciences (NASDAQ:TLSA) Trading 3.1% Higher - Still a Buy...

Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 7.4% - Still a Buy?

Tiziana Life Sciences (NASDAQ:TLSA) Shares Up 7.4% - What's Next...

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Alzheimer’s. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd

Bullish Sentiment

<ul class="summary-bullets"><li>The trial includes 48 patients with non-active secondary progressive multiple sclerosis (na-SPMS) across the U.S.</li><li>The efficacy of the trial will be assessed using PET imaging, MRI scans, clinical evaluations, and biomarker analyses.</li><li>Topline data is expected in Q3 2026, with results set to be presented at a major MS research conference in Toronto later in the year.</li></ul><p>Shares of Tiziana Life Sciences (TLSA) rose more than 9% on Thursday after the company announced it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2a clinical trial of intranasal foralumab.</p><p>The study is evaluating the treatment in patients with non-active secondary progressive multiple sclerosis (na-SPMS).</p><p>Topline data is expected in late Q3 2026. It will also be presented at the 10th joint meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and ECTRIMS in Toronto, Canada, in October 2026.</p><h2 class="st-heading-2">US Trial Evaluates Intranasal Foralumab In 48 Patients</h2><p>The trial, known as INFORM-MS, is the first Phase 2 placebo-controlled study of intranasal foralumab. It marks an important milestone in the clinical development of this anti-CD3 monoclonal antibody for neurodegenerative and neuroinflammatory diseases.</p><p>The multi-center study has enrolled 48 patients across multiple U.S. sites who are receiving either one of two intranasal foralumab dose levels or placebo over a 12-week treatment period. The trial will assess outcomes using PET imaging for microglial activation, MRI scans, clinical evaluations, and biomarker analysis.</p><h2 class="st-heading-2">Six-Month Extension Phase To Assess Benefits</h2><p>After the completion of the blinded phase, all participants, including those initially assigned to placebo, will be eligible to receive intranasal foralumab in a six-month open-label extension (OLE) phase. The extension will assess the drug’s long-term safety and whether its benefits are sustained in patients with na-SPMS.</p><p>Gabriele Cerrone, executive chairman and founder of Tiziana Life Sciences, said, “Intranasal delivery offers a novel, non-invasive route that targets the brain’s immune mechanisms directly.”</p><h2 class="st-heading-2">TLSA Retail Sentiment On Stocktwits</h2><p>On Stocktwits, retail sentiment surrounding TLSA stock turned ‘extremely bullish’ from ‘bullish’ a day ago, with ‘high’ message volume.</p><p>One bullish user <a href="https://stocktwits.com/rp6577/message/654052935">expects</a> TLSA stock to hit “a new 52-week high very shortly.”</p><p><stembedurl>https://stocktwits.com/rp6577/message/654052935</stembedurl></p><p><a href="https://stocktwits.com/symbol/TLSA">TLSA stock</a> has gained over 15% year-to-date and around 28% in the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Autonomix Medical reported positive preliminary results from its ongoing proof-of-concept human clinical trial. | Source: Pexels

Tiziana Life Sciences shares rose over 9% after the company announced it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2a clinical trial of intranasal foralumab.

Why Is TLSA Stock Rising Today?

Fundamental investor

Technical trader

A mix of both

Fundamental analysis looks at earnings, valuation, and business quality, while technical analysis focuses on chart patterns, price action, and indicators, and many investors blend the two. How do you decide what to buy: fundamentals or technicals? Vote and explain your reasoning in the comments.

Current Price	$0.6204
Prev Close	$0.638
Open	$0.655
Dividend Yield	0.00%
50-Day Moving Average	$0.9676
Beta	0.76
Avg. Volume	539,571.84
PE Ratio	-3.03

52-Week High	$1.90
52-Week Low	$0.5671
Market Capitalization	$81.86M
EPS (Annual)	-$0.1558
Price to Book	-28.91
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

TLSA Fundamentals